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Abstract: 
Atorvastatin Calcium was microencapsulated using rosin by o/w emulsion solvent evaporation technique. The effect 
of three formulation variables including the drug:polymer ratio, emulsifier (polyvinyl alcohol) concentration and 
organic solvent (dichloromethane) volume were examined. The prepared batches were characterized for 
microspheres particle size distribution, encapsulation efficiency and in vitro release behavior. The study reveals that 
drug:polymer ratio had a considerable effect on the entrapment efficiency, however particle size distribution of 
microspheres was more dependent on the volume of dichloromethane and polyvinyl alcohol concentration rather 
than on the drug: polymer ratio. Drug, polymer concentrations were varied to obtain optimum release profile for 
sustaining the action of the drug. 
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Conventional oral drug administration does not 
usually provide rate-controlled release or target 
specificity. In many cases, conventional drug 
delivery provides sharp increase in drug 
concentration often achieving toxic level and 
following a relatively short period at the therapeutic 
level of the drug concentration eventually drops off 
until re-administration. In order to obtain maximum 
therapeutic efficacy, it becomes necessary to deliver 
an agent to the target tissue in the optimal amount for 
the required period of time, thereby causing little 
toxicity and minimal side effects [1,2]. Desired drug 
release can be provided by rate-controlling 
membranes or by implanted biodegradable polymers 
containing dispersed medication. Microparticulate 
drug delivery systems are considered and accepted as 
a reliable one to deliver the drug to the target site 
with specificity, to maintain the desired concentration 
at the site of interest without untoward effects [2]. 
Microencapsulation is a useful method which 
prolongs the duration of drug effect significantly and 
improves patient compliance. Eventually the total 
dose and few adverse reactions may be reduced since 
a steady plasma concentration is maintained [3]. In 
recent years much research in drug delivery has been 
focused on degradable polymer microspheres. 
Administration of medication via such systems is 
advantageous because microspheres can be ingested 
or injected, can be tailored for desired release profiles 
and in some cases it can provide organ-targeted 
release [4-7]. The meaning of microencapsulation is 
converting liquids to solids, altering colloidal and 
surface properties, providing environmental 
protection and controlling the release characteristics 
by using the coating materials.Emulsion solvent [5], 
phase-separation method10 and spray drying method 
[8] are commonly used for the preparation of 
microspheres. The success of any microencapsulation 
method depends on many factors such as the drug 
solubility, partition co-efficiency, polymer 
composition, molecular weight etc. Among the 
various microencapsulation methods, emulsion 
solvent evaporation technique is often widely used to 
prepare microcapsules of water insoluble drugs 
(within the water insoluble polymer). Microspheres  
 
 
are formed by the evaporation of an organic solvent 
from dispersed oil droplets containing both polymer 
anddrug[4,7,9,10,11]. Atorvastatin calcium is a 
HMG-CoA reductase inhibitor used in the treatment 
of hyperlipidemia. It has an oral bioavailability of 
less than 12% after a 40mg oral dose. It also 
undergoes high first pass metabolism. It is highly 
soluble in acidic pH and absorbed more in the upper 
part of the GIT. The major hurdle of atorvastatin is 
rate limited bioavailability. The main objective of the 
present work is to formulate microspheres of 
atorvastatin. The microspheres of atorvastatin may 
improve solubility and higher dissolution rate by 
decreasing particle size and increasing surface area. 
They may increase the patient compliance by 
significantly enhancement in oral bioavailability of 
the drug. 
 
MATERIALS AND METHODS: 
 
Materials  
Atorvastatin calcium candida health pharmaceutical; 
Eudragit S100 Evonik Industries. Polyvinyl alcohol 
(PVA - MW 1, 30,000) from SD fine chemicals, 
Rosin from Yucca Enterprises, Dombivilli, and 
Thane, India were used in the study. 
Dichloromethane, Potassium dihydrogen phosphate, 
Sodium hydroxide and Camphor were procured from 
S.D. Fine Chemicals, Mumbai, India. 
 
Method 
Microspheres of Atorvastatin calcium were prepared 
based on o/w emulsion solvent evaporation technique 
by using rosin as a polymer. Different batches of 
microspheres were prepared by dissolving the 
polymer and the drug in dichloromethane and then 
adding this oil phase in the aqueous phase (100 ml) 
containing various percentages of PVA as the 
emulsifying agent; the mixture was emulsified by 
constant stirring at 400 rpm for 4 h by using a 
propeller stirrer (Remi, India). The dispersed drug 
and polymer solution was immediately transformed 
into fine droplets, which subsequently solidified into 
rigid microspheres due to the solvent evaporation. 
The particles were collected by filtration, washed and 
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Table 1: Composition of Atorvastatin calcium loaded microspheres 
 
Ingredients (mg) F1 F1 F1 F1 F1 F1 F1 
Atorvastatin calcium 200 400 600 200 200 200 200 
Rosin 200 200 200 400 600 400 600 
PVA  0.25% 0.25% 0.25% 0.25% 0.25% 0.25% 0.25% 
Dichloromethane 10 ml 10 ml 10 ml 10 ml 10 ml 10 ml 10 ml 
Water 100 ml 100 ml 100 ml 100 ml 100 ml 100 ml 100 ml 
Camphor --- --- --- --- --- 200 200 
 
Drug-Excipients Compatibility Studies 
Differential Scanning Calorimetery (DSC) 
The DSC measurements were performed on a 
differential scanning calorimeter with a thermal 
analyzer. All accurately weighed samples were 
placed in sealed aluminum pans, before heating under 
nitrogen flow (20ml/min) at a scanning rate of 10 °C 
min−1 from 25 to 250 °C. An empty aluminum pan 
was used as reference. 
 
Drug polymer Interaction (FTIR) study 
Fourier-transform infrared (FT-IR) spectra were 
obtained by using shimadzu FTIR- 8400 
Spectrophotometer. The samples were previously 
ground and mixed thoroughly with potassium 
bromide, an infrared transparent matrix, at 1:5 
(Sample/KBr) ratio, respectively. The KBr discs were 
prepared by compressing the powders at a pressure of 
5 tons for 5 min in a hydraulic press. 
 
Percentage Yield 
The yield of microspheres was determined by 
comparing the whole weight of microspheres formed 
against the combined weight of the copolymer and 
drug. 
                                        Mass of microspheres obtained 
Percentage yield =                                                                    X 100     
                                Total weight of drug and polymer used 
 
Particle size and size distribution 
The microspheres were suspended in liquid paraffin 
and examined using an optical microscope. Laser 
diffraction technique (Malvern Instruments Ltd. 
Malvern, UK) was used to study the size distribution 
of the microspheres. The dispersant used was 
cyclohexane and the average particle size was 
calculated and expressed in microns. 
 
Drug Entrapment efficiency 
The drug entrapment efficiency (DEE) was 
calculated by the following formula 
                         
DEE = (Pc / Tc) × 100 
    Here,  Pc is practical content, 
             Tc is the theoretical content. 
 
X-ray Diffraction Studies (XRD)  
X-ray diffraction analysis was performed using 
Bruker axs diffractometer D 8Advanced model (high 
beam monochromatic) using Cu radiation which was 
generated at 40 Kv and 40 mA at 1.540600A. The 
rate of the scanning was 0.30°C /min. 
 
Drug Content Determination 
ATR spherical agglomerates equivalent to 40 mg of 
ATR were accurately weighed, crushed and 
transferred to a 10 mL volumetric flask. To this, 50 
mL of methanol was added and sample was sonicated 
for 20 min so as todissolve the drug and the polymer. 
The volume was made up to 100 mL withmethanol 
and filtered through a 0.45 μm filters. The filtrate was 




The apparent solubility of Spherical crystals of 
Atorvastatin calcium determined In water.Each 
Spherical crystals in excess of drug equivalent to (40 
mg) was added to 10 ml of solvent in glass vials with 
rubber closers. Then the vials were kept on a shaker 
incubator maintained at 37 ± 0.5 °C for 24 h. After 
shaking, the vials were kept in an incubator at 37 ± 
0.5 °C for equilibrium for 10h. The solution was then 
filtered through 0.45 µm Millipore, filtered and the 
filtrate was assayed spectrophotometrically at 246.5 
nm. 
 
In-vitro release studies 
In-vitro dissolution studies were carried out with 
spherical agglomerates. Each test was carried out in 
United States Pharmacopoeia dissolution apparatus II 
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(Paddle) consisted of 900 ml , 0.1 N HCl maintained 
at 37.0 ± 0.5°C and stirring at 75 rpm. An accurately 
weighed quantity of each sample equivalent to 40 mg 
of Atorvastatin Calcium was subjected to the test. 
Samples 5 ml were withdrawn at predetermined time 
interval (5, 10, 15, 20 & 30 minutes) and 
immediately replace with the equal volumes of 
dissolution medium.. Diluted samples were analyzed 
at 246.5 nm by uv-spectrophotometer. 
 
Flow Property 
Flowability of ATR and its spherical agglomerates 
were determined in terms of the following 
parameters,Bulk density,Tapped density, Hausner 
ratio,Carr’s index and Angle of repose. 
 
RESULTS AND DISCUSSION: 
Differential Scanning Calorimetery (DSC) 
 The pure drug Atorvastatin calcium shown as an 
endothermic peak at 189.14oC. The peak neither is 
nor shifted in the case of DSC of the Atorvastatin 
calcium microspheres formulation containing 
Atorvastatin calcium. The DSC of physical mixture 
of the Losartan Potassium showed an endothermic 
peak at 189.14oC. The DSC spectra as shown in Fig 




Fig. 1:  DSC of Atorvastatin calcium 
 
 
Fig. 2: DSC of Atorvastatin calcium with Physical mixture 
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Drug polymer Interaction (FTIR) study 
From the spectra Atorvastatin calcium and physical 
mixture of Atorvastatin calcium, it was observed that 
all characteristic peaks of Losartan potassium were 
present in the combination spectrum, thus indicating 
compatibility of the Losartan potassium and polymer. 
 
 
Fig No.3: F IR of Atorvastatin calcium 
 
 
Fig No.4: FTIR of Atorvastatin calcium Physical Mixture. 
 
 
Table 2 Characteristics of Atorvastatin calcium microspheres 
Formulation 
code 
Percentage Yield Particle size(μm) 
Mean±SD 
% Drug Content Entrapment 
efficiency (%) 
F1 45.0 112±0.02 48.32 78.41±0.01 
F2 50.0 118±0.04 52.32 80.30±0.01 
F3 64.1 140±0.06 65.12 83.31±0.01 
F4 80.0 167±0.02 81.23 85.21±0.01 
F5 90.83 171±0.01 92.36 94.12±0.01 
F6 85.0 172±0.03 86.00 91.14±0.01 
F7 91.5 174±0.07 92.36 93.16±0.01 
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Fig 1: SEM photographs of Atorvastatin calcium microspheres 
 




Percent drug release at time (hr) 
 
F1 F2 F3 F4 F5 F6 F7 
        
1 50.20±0.9 49.2±0.6 44.31±0.3 46.21±0.9 43.21±0.6 42.13±0.3 43.12±0.2 
3 55.10±0.3 54.21±0.2 53.20±0.9 52.41±0.4 51.23±0.5 49.21±0.5 48.32±0.2 
6 60.01±0.34 59.01±0.1 57.23±0.3 56.14±0.3 55.32±0.4 54.25±0.5 53.23±0.1 
9 68.87±0.32 63.02±0.69 61.35±0.2 60.54±0.1 59.24±0.2 58.36±0.5 56.32±0.2 
12 75.58±0.7 67.58±0.6 63.21±0.7 62.30±0.5 61.25±0.2 6887±0.6 59.23±0.2 
15 79.58±0.7 72.71±0.1 71.03±0.9 70.21±0.2 69.58±.0.5 73.21±0.4 66.54±0.6 
18 88.4±0.4 77.15±0.52 76.8±0.1 75.21±0.3 74.21± 78.89±0.4 72.36±0.2 
21 98.52±0.2 84.14±0.3 85.74±0.3 84.33±0.4 83.25±0.5 88.54±0.4 86.56±0.5 
24 --- 91.23±0.2 92.69±0.5 91.36±0.3 89.72±0.3 98.31±0.4 93.36±0.3 
 
In order to improve the release rate of drug from 
microspheres, 2.0 % w/v of camphor was included in 
the formulations. The composition of the formulation 
is shown in Table 1. Camphor was dissolved in the 
polymer solution, its forms uniform distribution in 
the polymer solution. Upon microencapsulation the 
particles will be getting encapsulated by polymer 
along with camphor. On drying due to volatile nature 
camphor may get evaporated and forms pores on the 
surface of the microspheres, through which drug 
could easily diffuse to the aqueous phase or 
dissolution medium. Microspheres were prepared by 
the emulsion solvent evaporation method and 
evaluated. In vitro release studies for the prepared 
microspheres were carried out .The release results are 
shown in table 3. Formulation F6 showed better 
release rate than F7. The reason for this retarded drug 
release may be due to the hydrophobic nature of the 
polymer, which prevents the penetration of the 
dissolution medium into the microspheres leading to 
slower dissolution and diffusion of the drug 
molecules from the microspheres. 
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(Avg. ± S.D.) 
Bulk density 
(Avg. ± S.D.) 
Tapped density 
(Avg. ± S.D.) 
Compressibility 
index           (Avg. 
± S.D.) 
Haussner’s 
ratio        (Avg. 
± S.D.)          
Angle of repose 
(Avg. ± S.D.) 
F1 0.426 ± 0.02 0.349 ± 0.01 3.702 ± 0.02 1.064 ± 0.01 22.170 ± 0.14 
F2 0.232 ± 0.01 0.389 ± 0.03 4.349 ± 0.03 1.059 ± 0.01 21.120 ± 0.17 
F3 0.310 ± 0.02 0.329 ± 0.01 3.601 ± 0.01 1.038 ± 0.02 18.170 ± 0.15 
F4 0.416 ± 0.01 0.355 ± 0.02 3.875 ± 0.01 1.040 ± 0.01 20.140 ± 0.12 
F5 0.326± 0.02 0.387 ± 0.02 3.659 ± 0.02 1.045 ± 0.01 22.070 ± 0.11 
F6 0.327 ± 0.02 0.431 ± 0.01 3.071 ± 0.02 1.087 ± 0.01 21.210 ± 0.18 




This study shows that o/w emulsion solvent 
evaporation can be used as a simple method to 
prepare Aceclofenac sustained release microspheres 
by suing rosin as an encapsulating polymer. The drug 
entrapment efficiency of prepared microspheres were 
affected only by the drug:polymer ratio. The 
emulsifier concentration and organic phase volume 
influenced the particle size distribution of 
microspheres. Based on the above findings, it was 
observed that formulation F6 showed optimum 
release characteristics. The release rate of drug from 
the microspheres could be properly controlled for 
about 24h. Appropriate variation in the proportions of 
drug; polymer and stabilizer can lead to a product 
with the desired controlled release features 
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